Tramadol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tramadol: From Osteoarthritis to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Tramadol is an opioid analgesic originally used for pain in osteoarthritis and other joint disorders. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osteoarthritis, arthropathy (the licence records contain no approved indication text; these indications come from the knowledge graph) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 13 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the data compiled for this report. Based on general pharmacology, tramadol is a mu-opioid receptor agonist that also inhibits serotonin and norepinephrine reuptake. It provides symptomatic pain relief and has been used for osteoarthritis and related joint pain.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare genetic skeletal dysplasia caused by loss of function of the CDMP1/GDF5 gene, which affects skeletal growth. Tramadol does not address this underlying genetic defect. The high TxGNN score most likely reflects closeness in the knowledge graph to the original musculoskeletal indications, not a pharmacological rationale. No credible mechanistic link was identified.
Other top-ranked predictions show the same pattern. Brachyolmia, brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, pseudoachondroplasia, spondyloarthropathy and several juvenile arthritis subtypes all have scores above 99.9%. None has supporting trials, and the only literature record found (for juvenile idiopathic arthritis) concerns ketoprofen, not tramadol. At best, tramadol could offer symptomatic pain relief in some of these conditions, such as pseudoachondroplasia, which causes early joint pain.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the predicted indication.
Singapore Market Information
There are 13 valid single-ingredient registrations. The records contain no approved indication text. The 5 main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10045P | ACUGESIC INJECTION 50 mg/ml (without preservative) | Injection | Not stated in the records |
| SIN09131P | ACUGESIC TABLET 50 mg | Tablet | Not stated in the records |
| SIN10057P | TRADOL INJECTION 50 mg/ml | Injection | Not stated in the records |
| SIN08367P | TRAMADOL STADA INJECTION 100 mg/2 ml | Injection | Not stated in the records |
| SIN08365P | TRAMADOL 50 STADA CAPSULE 50 mg | Capsule | Not stated in the records |
Available routes include oral (tablet, capsule, film-coated tablet) and injectable (injection, solution for injection).
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): hypertension, liver failure, liver disease and cirrhosis, epilepsy, anxiety and neurotic disorders, diabetes and diabetic ketoacidosis, substance abuse/dependence and withdrawal states, respiratory failure, paracetamol poisoning, serotonin syndrome, intracranial hypertension, alcohol withdrawal, and central nervous system infections. These should be verified against the package insert.
- Drug Interactions: The interaction screen returned 100 interacting drugs. Major interactions listed include alvimopan, bupropion, cisapride, dexfenfluramine, diethylpropion, dolasetron, dronabinol, ephedrine and fenfluramine. Moderate interactions include atropine, bisacodyl, cimetidine, clarithromycin and famotidine.
- Pediatric concern: Several of the predicted indications are juvenile conditions. Opioid use in children raises safety concerns, including ultra-rapid CYP2D6 metabolism and respiratory depression.
Package insert warnings were not available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support (Evidence Level L5) and no credible mechanistic link. Tramadol is only a symptomatic analgesic and cannot modify the underlying genetic skeletal defect. The high model score appears to reflect graph proximity to osteoarthritis and arthropathy.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Detailed mechanism of action data
- Any clinical or preclinical evidence for tramadol in this condition
- If symptomatic pain relief is the goal, a reframed question, such as pain management in skeletal dysplasia with joint pain, with a dedicated evidence search
- A pediatric safety assessment, given the young patient population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.